The blow fill seal technology market is expected to grow from its estimated USD 3,107.8 million in 2024 to USD 5,258.5 million in 2034. Between 2024 and 2034, sales are expected to increase at a ...

The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contributing ...

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Sweid One is a pivotal project for us, designed to raise the bar for commercial office space within JLT,” said Maher Sweid, ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

ANB032 was well tolerated across all doses with no safety signals observed; AD trial and all further investment in ANB032 will be discontinued; Anticipate top-line Phase 2b data i ...